GSK

GSK Plc seeks EMA approval for RSV vaccine in adults 18+

GSK's RSV vaccine, Arexvy, is set for expanded use in adults 18+, following EMA's acceptance. This breakthrough addresses a critical need in respiratory health...

GSK Plc launches second tranche of £2 billion Share Buyback

GSK plc launches a £2 billion share buyback program to enhance shareholder value, starting the second tranche valued at £0.45 billion on June 4, 2025...

GSK Plc Nucala approved by FDA for Eosinophilic COPD

GSK's Nucala (mepolizumab) gains FDA approval as a crucial add-on treatment for adults with inadequately controlled COPD and eosinophilic phenotype...

GSK Plc receives Japan approval for Blenrep combinations in multiple myeloma

GSK's Blenrep combinations gain approval in Japan for relapsed multiple myeloma, offering promising treatment options backed by successful clinical trial results...

GSK Plc to acquire Efimosfermin for $2 billion, targeting steatotic liver disease

GSK is set to acquire Boston Pharmaceuticals' promising liver disease treatment, efimosfermin alfa, enhancing its hepatology pipeline and addressing critical patient needs...

GSK Plc delivers strong Q1 2025 with profit and Specialty Medicines growth

GSK PLC reports strong Q1 2025 results, driven by Specialty Medicines growth and significant R&D investments, highlighting confidence in future performance...

GSK Plc’s Penmenvy vaccine backed by US Advisory Panel

GSK's Penmenvy vaccine is set to transform adolescent immunisation against meningococcal disease in the US, streamlining protection with fewer doses...

GSK Plc Nucala application for COPD accepted by EMA

GSK announces the EMA's review of Nucala (mepolizumab) as a potential add-on treatment for COPD, promising hope for 40 million patients battling this condition...

GSK Plc completes acquisition of IDRx, Inc.

GSK plc has completed its acquisition of IDRx, Inc., aiming to advance treatments for gastrointestinal stromal tumours with the novel IDRX-42 inhibitor...

GSK Plc 5-in-1 meningococcal vaccine approved by FDA

GSK's Penmenvy vaccine wins FDA approval, offering protection for ages 10-25 against five major meningococcal serogroups, aiming to boost vaccination rates...

GSK Plc reports strong growth in Specialty Medicines and R&D progress

GSK plc reports robust 2024 performance with strong Specialty Medicines growth, promising R&D advancements, and strategic shareholder returns...

GSK plc Depemokimab applications accepted for review in China and Japan

GSK's depemokimab, an ultra-long-acting biologic, is up for regulatory review in China and Japan for asthma and CRSwNP, based on positive trial results...

GSK Plc Shingrix new prefilled syringe presentation accepted for review by EMA

GSK's innovative prefilled Shingrix syringe gains EMA review, aiming to simplify shingles prevention for healthcare professionals across Europe...

GSK’s Jemperli gains EU approval for advanced endometrial cancer treatment

GSK's Jemperli plus chemotherapy gains EU approval for broader use in first-line treatment of advanced or recurrent endometrial cancer, improving survival rates...

FDA accepts review of GSK Plc’s prefilled Shingrix syringe for vaccine approval

GSK's Shingrix aims for FDA-approved prefilled syringe to simplify shingles vaccination, enhancing convenience for healthcare providers...

GSK Plc’s ADC receives US FDA Breakthrough Therapy Designation

GSK's ADC GSK5764227 gains FDA Breakthrough Therapy status for treating relapsed or refractory osteosarcoma, addressing critical unmet medical needs...
Search

Funds

GSK

GSK Plc seeks EMA approval for RSV vaccine in adults 18+

GSK's RSV vaccine, Arexvy, is set for expanded use in adults 18+, following EMA's acceptance. This breakthrough addresses a critical need in respiratory health...

GSK Plc launches second tranche of £2 billion Share Buyback

GSK plc launches a £2 billion share buyback program to enhance shareholder value, starting the second tranche valued at £0.45 billion on June 4, 2025...

GSK Plc Nucala approved by FDA for Eosinophilic COPD

GSK's Nucala (mepolizumab) gains FDA approval as a crucial add-on treatment for adults with inadequately controlled COPD and eosinophilic phenotype...

GSK Plc receives Japan approval for Blenrep combinations in multiple myeloma

GSK's Blenrep combinations gain approval in Japan for relapsed multiple myeloma, offering promising treatment options backed by successful clinical trial results...

GSK Plc to acquire Efimosfermin for $2 billion, targeting steatotic liver disease

GSK is set to acquire Boston Pharmaceuticals' promising liver disease treatment, efimosfermin alfa, enhancing its hepatology pipeline and addressing critical patient needs...

GSK Plc delivers strong Q1 2025 with profit and Specialty Medicines growth

GSK PLC reports strong Q1 2025 results, driven by Specialty Medicines growth and significant R&D investments, highlighting confidence in future performance...

GSK Plc’s Penmenvy vaccine backed by US Advisory Panel

GSK's Penmenvy vaccine is set to transform adolescent immunisation against meningococcal disease in the US, streamlining protection with fewer doses...

GSK Plc Nucala application for COPD accepted by EMA

GSK announces the EMA's review of Nucala (mepolizumab) as a potential add-on treatment for COPD, promising hope for 40 million patients battling this condition...

GSK Plc completes acquisition of IDRx, Inc.

GSK plc has completed its acquisition of IDRx, Inc., aiming to advance treatments for gastrointestinal stromal tumours with the novel IDRX-42 inhibitor...

GSK Plc 5-in-1 meningococcal vaccine approved by FDA

GSK's Penmenvy vaccine wins FDA approval, offering protection for ages 10-25 against five major meningococcal serogroups, aiming to boost vaccination rates...

GSK Plc reports strong growth in Specialty Medicines and R&D progress

GSK plc reports robust 2024 performance with strong Specialty Medicines growth, promising R&D advancements, and strategic shareholder returns...

GSK plc Depemokimab applications accepted for review in China and Japan

GSK's depemokimab, an ultra-long-acting biologic, is up for regulatory review in China and Japan for asthma and CRSwNP, based on positive trial results...

GSK Plc Shingrix new prefilled syringe presentation accepted for review by EMA

GSK's innovative prefilled Shingrix syringe gains EMA review, aiming to simplify shingles prevention for healthcare professionals across Europe...

GSK’s Jemperli gains EU approval for advanced endometrial cancer treatment

GSK's Jemperli plus chemotherapy gains EU approval for broader use in first-line treatment of advanced or recurrent endometrial cancer, improving survival rates...

FDA accepts review of GSK Plc’s prefilled Shingrix syringe for vaccine approval

GSK's Shingrix aims for FDA-approved prefilled syringe to simplify shingles vaccination, enhancing convenience for healthcare providers...

GSK Plc’s ADC receives US FDA Breakthrough Therapy Designation

GSK's ADC GSK5764227 gains FDA Breakthrough Therapy status for treating relapsed or refractory osteosarcoma, addressing critical unmet medical needs...
Search

Funds

GSK

FTSE 100

Funds